Nancy K Sweitzer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11531622/publications.pdf

Version: 2024-02-01

81743 62479 7,911 87 39 80 citations g-index h-index papers 87 87 87 7984 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Spironolactone for Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2014, 370, 1383-1392.	13.9	1,993
2	Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial. Circulation, 2015, 131, 34-42.	1.6	758
3	Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal, 2016, 37, 455-462.	1.0	396
4	Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. Circulation, 2015, 132, 402-414.	1.6	371
5	High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure. Circulation: Heart Failure, 2011, 4, 180-187.	1.6	319
6	Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 104-115.	1.6	288
7	Heart Failure With Recovered Ejection Fraction. Circulation, 2014, 129, 2380-2387.	1.6	244
8	Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2016, 9, e002763.	1.6	224
9	Cardiac Structure and Function and Prognosis in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 740-751.	1.6	218
10	Ventricular-Arterial Coupling, Remodeling, and Prognosis in Chronic Heart Failure. Journal of the American College of Cardiology, 2013, 62, 1165-1172.	1.2	189
11	Multiple Biomarkers for Risk Prediction in Chronic Heart Failure. Circulation: Heart Failure, 2012, 5, 183-190.	1.6	169
12	Baseline Characteristics of Patients in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. Circulation: Heart Failure, 2013, 6, 184-192.	1.6	154
13	Thyroid Dysfunction in Heart Failure and Cardiovascular Outcomes. Circulation: Heart Failure, 2018, 11, e005266.	1.6	143
14	Comparison of Clinical Features and Outcomes of Patients Hospitalized With Heart Failure and Normal Ejection Fraction (≥55%) Versus Those With Mildly Reduced (40% to 55%) and Moderately to Severely Reduced (<40%) Fractions. American Journal of Cardiology, 2008, 101, 1151-1156.	0.7	126
15	Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2019, 7, 228-238.	1.9	123
16	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Circulation: Heart Failure, 2018, 11, e004962.	1.6	117
17	Does Race Influence Decision Making for Advanced Heart Failure Therapies?. Journal of the American Heart Association, 2019, 8, e013592.	1.6	108
18	The frailty syndrome and outcomes in the TOPCAT trial. European Journal of Heart Failure, 2018, 20, 1570-1577.	2.9	106

#	Article	IF	Citations
19	Neuregulin- $\hat{l^2}$ Is Associated With Disease Severity and Adverse Outcomes in Chronic Heart Failure. Circulation, 2009, 120, 310-317.	1.6	103
20	Loss-of-function DNA sequence variant in the <i>CLCNKA</i> chloride channel implicates the cardio-renal axis in interindividual heart failure risk variation. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 2456-2461.	3.3	95
21	Association of Gender and Race With Allocation of Advanced Heart Failure Therapies. JAMA Network Open, 2020, 3, e2011044.	2.8	91
22	Strain Improves Risk Prediction Beyond Ejection Fraction in Chronic Systolic Heart Failure. Journal of the American Heart Association, 2014, 3, e000550.	1.6	81
23	Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart) Tj ETQq1	l 0.784314 1.6	rgBT/Overloo
24	Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. Circulation: Heart Failure, 2015, 8, 1052-1058.	1.6	70
25	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2018, 6, 689-697.	1.9	68
26	Impact of Malnutrition Using Geriatric Nutritional Risk Index in HeartÂFailure With Preserved Ejection Fraction. JACC: Heart Failure, 2019, 7, 664-675.	1.9	68
27	The Vascular Marker Soluble Fms-Like Tyrosine Kinase 1 Is Associated With Disease Severity and Adverse Outcomes in Chronic Heart Failure. Journal of the American College of Cardiology, 2011, 58, 386-394.	1.2	65
28	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with) Tj ETQq0 0 0 rg	BT /Qverloc	k 10 Tf 50 382
29	Temporal Trends in Contemporary Use of Ventricular Assist Devices by Race and Ethnicity. Circulation: Heart Failure, 2018, 11, e005008.	1.6	58
30	Sudden Death in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2018, 6, 653-661.	1.9	56
31	Decreased Cardiac Functional Reserve in Heart Failure With Preserved Systolic Function. Journal of Cardiac Failure, 2011, 17, 301-308.	0.7	55
32	Acute Decompensated Heart Failure: Update on New and Emerging Evidence and Directions for Future Research. Journal of Cardiac Failure, 2013, 19, 371-389.	0.7	53
33	Factors Related to Physician Clinical Decision-Making for African-American and Hispanic Patients: a Qualitative Meta-Synthesis. Journal of Racial and Ethnic Health Disparities, 2018, 5, 1215-1229.	1.8	49
34	Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. Journal of Cardiac Failure, 2018, 24, 313-320.	0.7	49
35	What Is an Angiotensin Converting Enzyme Inhibitor?. Circulation, 2003, 108, e16-8.	1.6	46
36	Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure. Journal of Cardiac Failure, 2016, 22, 256-262.	0.7	46

#	Article	IF	CITATIONS
37	Increases in Central Aortic Impedance Precede Alterations in Arterial Stiffness Measures in Type 1 Diabetes. Diabetes Care, 2007, 30, 2886-2891.	4.3	41
38	Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2018, 3, 1000.	3.0	41
39	Decreased Immune Responses to Influenza Vaccination in Patients With Heart Failure. Journal of Cardiac Failure, 2009, 15, 368-373.	0.7	40
40	Economic Issues in Heart Failure in the United States. Journal of Cardiac Failure, 2022, 28, 453-466.	0.7	40
41	Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations From the Heart Failure Society of America Guideline Committee. Journal of Cardiac Failure, 2015, 21, 674-693.	0.7	39
42	Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2018, 11, e005288.	1.6	35
43	Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial. Circulation: Heart Failure, 2018, 11, e004457.	1.6	31
44	Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial. European Journal of Heart Failure, 2018, 20, 483-490.	2.9	28
45	Biomarker Predictors of Cardiac Hospitalization in Chronic Heart Failure: A Recurrent Event Analysis. Journal of Cardiac Failure, 2014, 20, 569-576.	0.7	26
46	Double dose vs. standard dose influenza vaccination in patients with heart failure: a pilot study. European Journal of Heart Failure, 2013, 15, 560-564.	2.9	25
47	Decreased T-Cell Responses to Influenza Vaccination in Patients with Heart Failure. Pharmacotherapy, 2010, 30, 10-16.	1.2	21
48	Effect of Renal Function on Prognosis in Chronic Heart Failure. American Journal of Cardiology, 2015, 115, 62-68.	0.7	21
49	Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2019, 12, e006125.	1.6	21
50	Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulinâ€⁻+â€⁻Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study). American Journal of Cardiology, 2019, 123, 611-617.	0.7	21
51	Application of the H ₂ FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. European Journal of Heart Failure, 2019, 21, 1288-1291.	2.9	18
52	Imbalance in Heart Transplant to Heart Failure Mortality Ratio Among African American, Hispanic, and White Patients. Circulation, 2021, 143, 2412-2414.	1.6	18
53	Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2021, 14, e008293.	1.6	18
54	Lack of Persistence of Influenza Vaccine Antibody Titers in Patients With Heart Failure. Journal of Cardiac Failure, 2014, 20, 105-109.	0.7	15

#	Article	IF	CITATIONS
55	From statistical significance to clinical relevance: A simple algorithm to integrate brain natriuretic peptide and the Seattle Heart Failure Model for risk stratification in heart failure. Journal of Heart and Lung Transplantation, 2016, 35, 714-721.	0.3	15
56	Effect of Heart Failure With Preserved Ejection Fraction on Nitric Oxide Metabolites. American Journal of Cardiology, 2016, 118, 1855-1860.	0.7	15
57	Medical Misinformation: Vet the Message!. Journal of the American Heart Association, 2019, 8, e011838.	1.6	15
58	Is the Affordable Care Act Medicaid Expansion Linked to Change in Rate of Ventricular Assist Device Implantation for Blacks and Whites?. Circulation: Heart Failure, 2020, 13, e006544.	1.6	14
59	Left Ventricular Responses to Acute Changes in Late Systolic Pressure Augmentation in Older Adults. American Journal of Hypertension, 2013, 26, 866-871.	1.0	10
60	Is the affordable care act medicaid expansion associated with receipt of heart failure guideline-directed medical therapy by race and ethnicity?. American Heart Journal, 2022, 244, 135-148.	1.2	10
61	Heart Transplantation Survival and the Use of Traumatically Brainâ€Injured Donors: UNOS Registry Propensityâ€Matched Analysis. Journal of the American Heart Association, 2019, 8, e012894.	1.6	9
62	Whole transcriptome profiling of prospective endomyocardial biopsies reveals prognostic and diagnostic signatures of cardiac allograft rejection. Journal of Heart and Lung Transplantation, 2022, 41, 840-848.	0.3	9
63	Clinical Outcome Predictions for the VerlCiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. Journal of Cardiac Failure, 2021, 27, 949-956.	0.7	8
64	Imbalance in Heart Transplant to Heart Failure Mortality Ratio by Sex. Journal of the American Heart Association, 2021, 10, e020146.	1.6	7
65	Influence of Age on Efficacy and Safety ofÂSpironolactone in HeartÂFailure. JACC: Heart Failure, 2019, 7, 1022-1028.	1.9	6
66	Sex Disparities in Organ Donation: Finding an Equitable Donor Pool. Journal of the American Heart Association, 2021, 10, e020820.	1.6	6
67	More Appropriate Cardiovascular Risk Screening Through Understanding Complex Phenotypes. Journal of the American College of Cardiology, 2017, 70, 1438-1440.	1.2	5
68	Influence of ejection fraction on causeâ€specific mortality in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2018, 20, 815-816.	2.9	5
69	Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial. European Journal of Heart Failure, 2020, 22, 557-559.	2.9	5
70	Nonmalignant Diagnoses in Patients. Journal of Clinical Oncology, 2000, 18, 2638-2639.	0.8	4
71	Determinants of Exercise Intolerance in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2011, 58, 2547-2548.	1.2	4
72	New Therapeutic Target in Heart Failure. Circulation, 2018, 137, 1331-1333.	1.6	4

#	Article	IF	CITATIONS
73	Ex ante economic evaluation of genetic testing for the ARG389 beta1-adrenergic receptor polymorphism to support bucindolol treatment decisions in Stage III/IV heart failure. Expert Review of Precision Medicine and Drug Development, 2018, 3, 319-329.	0.4	3
74	Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure. American Journal of Cardiovascular Drugs, 2021, 21, 205-217.	1.0	3
75	Relationships between 2018 UNOS heart policy and transplant outcomes in metropolitan, micropolitan, and rural settings. Journal of Heart and Lung Transplantation, 2022, 41, 1228-1236.	0.3	3
76	When the VEST Does Not Fit. Circulation: Heart Failure, 2018, 11, e005116.	1.6	2
77	Choosing a Career in Heart Failure. Circulation: Heart Failure, 2019, 12, e006139.	1.6	2
78	The association between heart rate behavior and gait performance: The moderating effect of frailty. PLoS ONE, 2022, 17, e0264013.	1.1	2
79	Continuing Medical Education Activity in Echocardiography. Echocardiography, 2013, 30, 512-512.	0.3	1
80	Looking Ahead: Circulation: Heart Failure in 2022. Circulation: Heart Failure, 2022, 15, e009405.	1.6	1
81	Re: Decreased Immune Responses to Influenza Vaccination in Patients With Heart Failure. Journal of Cardiac Failure, 2009, 15, 549-551.	0.7	0
82	Editor's Perspective. Circulation: Heart Failure, 2017, 10, .	1.6	0
83	Apophenia and the Crafting of a Circulation: Heart Failure Issue. Circulation: Heart Failure, 2018, 11, e005027.	1.6	0
84	Showcasing Heart Failure Science at the American Heart Association Scientific Sessions. Circulation: Heart Failure, 2020, 13, e008157.	1.6	0
85	Science in the Time of Coronavirus. Circulation: Heart Failure, 2020, 13, e007115.	1.6	0
86	Grace Under Pressure. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE122009513.	1.6	0
87	2021: A Look Back. Circulation: Heart Failure, 2021, 14, e009358.	1.6	0